Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRI Biofrontera	$0.93 +1.4%	$0.80	$0.54 ▼ $2.22	$9.43M	0.5	247,067 shs	47,122 shs
CELZ Creative Medical Technology	$3.09 +5.8%	$2.68	$1.69 ▼ $6.90	$8.00M	2.04	110,299 shs	37,682 shs
DWTX Dogwood Therapeutics	$4.85 +1.7%	$4.85	$1.62 ▼ $29.28	$9.26M	1.8	1.80 million shs	18,455 shs
PTN Palatin Technologies	$0.09 -44.6%	$0.09	$0.09 ▼ $2.48	$2.45M	0.94	2.28 million shs	14.57 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRI Biofrontera	-3.11%	-8.75%	+6.64%	+27.59%	-29.99%
CELZ Creative Medical Technology	-12.31%	0.00%	+0.34%	+46.00%	0.00%
DWTX Dogwood Therapeutics	-1.24%	-1.85%	+0.21%	-1.65%	+476,999,900.00%
PTN Palatin Technologies	0.00%	0.00%	0.00%	0.00%	+9,409,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BFRI Biofrontera	2.3235 of 5 stars	3.5	3.0	0.0	0.0	2.7	0.0	0.6
CELZ Creative Medical Technology	0.9646 of 5 stars	0.0	2.0	0.0	0.0	3.9	0.0	1.3
DWTX Dogwood Therapeutics	1.8153 of 5 stars	3.5	0.0	0.0	0.0	2.4	0.0	0.6
PTN Palatin Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFRI Biofrontera	3.00	Buy	$2.75	195.70% Upside
CELZ Creative Medical Technology	0.00	N/A	N/A	N/A
DWTX Dogwood Therapeutics	3.00	Buy	$10.00	106.19% Upside
PTN Palatin Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PTN, CELZ, BFRI, and DWTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/19/2025	BFRI Biofrontera	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $2.75

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFRI Biofrontera	$37.32M	0.25	N/A	N/A	$0.57 per share	1.63
CELZ Creative Medical Technology	$10K	800.31	N/A	N/A	$3.63 per share	0.85
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	($7.56) per share	N/A
PTN Palatin Technologies	$350K	6.99	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFRI Biofrontera	-$17.76M	-$2.26	N/A	N/A	N/A	-30.33%	-305.13%	-82.67%	8/13/2025 (Estimated)
CELZ Creative Medical Technology	-$5.49M	-$3.18	N/A	N/A	N/A	N/A	-82.52%	-78.96%	N/A
DWTX Dogwood Therapeutics	-$12.35M	-$18.04	N/A	N/A	N/A	N/A	N/A	-34.74%	8/13/2025 (Estimated)
PTN Palatin Technologies	N/A	-$1.55	N/A	∞	N/A	N/A	N/A	N/A	N/A

Latest PTN, CELZ, BFRI, and DWTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	BFRI Biofrontera	-$0.45	N/A	N/A	N/A	$8.30 million	N/A
8/13/2025	Q2 2025	DWTX Dogwood Therapeutics	-$1.26	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	CELZ Creative Medical Technology	-$0.63	-$0.48	+$0.15	-$0.48	N/A	N/A
5/15/2025	Q1 2025	BFRI Biofrontera	-$0.14	-$0.47	-$0.33	-$0.47	$10.55 million	$8.59 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFRI Biofrontera	N/A	N/A	N/A	N/A	N/A
CELZ Creative Medical Technology	N/A	N/A	N/A	N/A	N/A
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	N/A
PTN Palatin Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFRI Biofrontera	8.99	1.40	0.80
CELZ Creative Medical Technology	N/A	27.43	27.42
DWTX Dogwood Therapeutics	N/A	7.43	7.43
PTN Palatin Technologies	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BFRI Biofrontera	10.08%
CELZ Creative Medical Technology	1.42%
DWTX Dogwood Therapeutics	9.05%
PTN Palatin Technologies	11.50%

Insider Ownership

Company	Insider Ownership
BFRI Biofrontera	4.80%
CELZ Creative Medical Technology	1.80%
DWTX Dogwood Therapeutics	3.90%
PTN Palatin Technologies	7.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BFRI Biofrontera	70	10.14 million	9.65 million	No Data
CELZ Creative Medical Technology	5	2.59 million	2.54 million	Not Optionable
DWTX Dogwood Therapeutics	5	1.91 million	1.84 million	N/A
PTN Palatin Technologies	30	26.01 million	N/A	N/A

PTN, CELZ, BFRI, and DWTX Headlines

Recent News About These Companies

Palatin Technologies, Inc. (PTN) Q3 2025 Earnings Call Transcript

May 15, 2025 | seekingalpha.com

Palatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ...

May 15, 2025 | gurufocus.com

Q3 2025 Palatin Technologies Inc Earnings Call Transcript

May 14, 2025 | gurufocus.com

Palatin Expects $11.5 Mln Offering To Aid NYSE Compliance And Fuel Obesity Drug Development

May 9, 2025 | nasdaq.com

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025

May 9, 2025 | prnewswire.com

Palatin Technologies Announces Encouraging Pre-Clinical Data Of PL9588 For Glaucoma Treatment

May 7, 2025 | nasdaq.com

Palatin Technologies faces delisting from NYSE American due to low stock price

May 7, 2025 | in.investing.com

Palatin Technologies faces delisting from NYSE American due to low stock price

May 7, 2025 | in.investing.com

NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)

May 7, 2025 | businesswire.com

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice

May 7, 2025 | prnewswire.com

Palatin Technologies Announces Pricing of up to $23 Million Public Offering

May 7, 2025 | prnewswire.com

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy

May 5, 2025 | prnewswire.com

PL9643 shows promise in dry eye disease treatment

April 30, 2025 | investing.com

Palatin Reports Positive Results From Responder Analyses Of Phase 3 MELODY-1 Study In DED

April 30, 2025 | nasdaq.com

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

April 29, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTN, CELZ, BFRI, and DWTX Company Descriptions

Biofrontera NASDAQ:BFRI

$0.93 +0.01 (+1.41%)

Closing price 04:00 PM Eastern

Extended Trading

$0.94 +0.01 (+1.29%)

As of 04:54 PM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Creative Medical Technology NASDAQ:CELZ

$3.09 +0.17 (+5.82%)

Closing price 04:00 PM Eastern

Extended Trading

$2.98 -0.12 (-3.72%)

As of 04:35 PM Eastern

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Dogwood Therapeutics NASDAQ:DWTX

$4.85 +0.08 (+1.68%)

Closing price 03:59 PM Eastern

Extended Trading

$4.83 -0.02 (-0.41%)

As of 04:34 PM Eastern

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Palatin Technologies NYSE:PTN

$0.09 -0.08 (-44.65%)

As of 05/7/2025

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time